TD Asset Management Inc Purchases 26,602 Shares of DaVita Inc. $DVA

TD Asset Management Inc boosted its position in shares of DaVita Inc. (NYSE:DVA) by 155.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 43,754 shares of the company’s stock after purchasing an additional 26,602 shares during the quarter. TD Asset Management Inc’s holdings in DaVita were worth $5,814,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Hantz Financial Services Inc. boosted its position in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in DaVita during the 2nd quarter worth $43,000. Employees Retirement System of Texas bought a new position in DaVita during the second quarter worth about $49,000. SJS Investment Consulting Inc. grew its stake in DaVita by 3,091.7% in the third quarter. SJS Investment Consulting Inc. now owns 383 shares of the company’s stock valued at $51,000 after acquiring an additional 371 shares during the period. Finally, MAI Capital Management grew its stake in DaVita by 23.4% in the second quarter. MAI Capital Management now owns 438 shares of the company’s stock valued at $62,000 after acquiring an additional 83 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Down 1.1%

NYSE:DVA opened at $152.25 on Wednesday. The company has a market cap of $10.17 billion, a P/E ratio of 15.36, a price-to-earnings-growth ratio of 0.54 and a beta of 0.94. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $159.42. The business has a 50 day moving average price of $125.68 and a two-hundred day moving average price of $126.16.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same period last year, the company earned $2.24 earnings per share. The firm’s revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. UBS Group raised their price target on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Barclays upped their price target on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $155.80.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.